Search

Your search keyword '"Poulain, Stéphanie"' showing total 221 results

Search Constraints

Start Over You searched for: Author "Poulain, Stéphanie" Remove constraint Author: "Poulain, Stéphanie"
221 results on '"Poulain, Stéphanie"'

Search Results

1. Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia

2. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression

3. Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)

5. High frequency of clonal hematopoiesis in Erdheim-Chester disease

8. Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains

9. Next-CLL, a New Next-Generation Sequencing–Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid Leukemia

10. Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

11. Supplemental Table 1 Gene expression profilling from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

12. Supplementary Table 1, Supplementary Figures 1-4 from TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

13. List of pathways analyzed for GSEA from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

14. TCL1 expression patterns in Waldenström macroglobulinemia

16. The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots

17. Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

18. Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

19. Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider

20. MYD88 L265P mutation in Waldenstrom macroglobulinemia

23. Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains

24. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia

25. Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia

27. Mast cell density and its clinical relevance in Waldenström's macroglobulinemia

28. Efficacy of ibrutinib in the treatment of Bing–Neel syndrome

30. Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

32. Next-CLL, a New Next-Generation Sequencing–Based Method for Assessment of IGHVGene Mutational Status in Chronic Lymphoid Leukemia

33. Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

34. Lenalidomide is safe and active in Waldenström macroglobulinemia

37. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )

38. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

39. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).

40. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.

41. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome

42. Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells

43. Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia

44. Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia

45. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

46. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

47. Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

48. Shared clonal IGH rearrangement in BCP‐ALL occurring after CLL: pitfalls and implications for MRD monitoring

50. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Catalog

Books, media, physical & digital resources